Screener
Veracyte VCYT Business Segments — Gross Profit
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of biopharmaceutical and other revenue | 8 | 2,698 |
| Intangible asset amortization - cost of revenue | 2,707 | 2,585 |
| Total cost of revenue | 37,912 | 34,965 |
| Gross profit | 101,159 | 79,508 |
| Operating expenses: | ||
| Research and development | 27,098 | 17,720 |
| Selling and marketing | 27,156 | 24,454 |
| General and administrative | 23,680 | 33,808 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's business segments — gross profit?
- Veracyte (VCYT) reported business segments — gross profit of $101.16M in Q1 2026.
- How has Veracyte's business segments — gross profit changed year-over-year?
- Veracyte's business segments — gross profit increased by 27.2% year-over-year, from $79.51M to $101.16M.
- What is the long-term trend for Veracyte's business segments — gross profit?
- Over 3 years (2022 to 2025), Veracyte's business segments — gross profit has grown at a 27.3% compound annual growth rate (CAGR), from $175.68M to $362.53M.
- What does business segments — gross profit mean?
- Calculated as the total revenue of the reportable segment minus the direct costs associated with producing its goods or services. It serves as a primary indicator of the segment's production efficiency and pricing power.
Ask your AI about Veracyte's business segments — gross profit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude